MutS homolog 2 (MSH2) is a crucial participant in human DNA repair, and lots of the studies functionally associated with it were begun with
hereditary nonpolyposis colorectal cancer (HNPCC). MSH2 has also been reported to take part in the progresses of various
tumors' formation. With the help of GTEx, CCLE, and TCGA pan-
cancer databases, the analysis of MSH2 gene distribution in both
tumor tissues and normal control tissues was carried out. Kaplan-Meyer survival plots and COX regression analysis were conducted for the assessment into the MSH2's impact on
tumor patients' clinical prognosis. In an investigation to the association of MSH2 expression with immune infiltration level of various
tumors and a similar study on
tumor immune neoantigens,
microsatellite instability was subsequently taken. It was found that high expression of MSH2 is prevalent in most
cancers. MSH2's efficacy on clinical prognosis as well as immune infiltration in
tumor patients revealed a fact that expression of MSH2 in prostate
adenocarcinoma (PRAD), brain lower-grade
glioma (LGG), breast-invasive
carcinoma (BRCA), and
head and neck squamous cell carcinoma (HNSC) posed a significant correlation with the immune cell infiltration level of patients. Likewise as above, MSH2's expression comes in a similar trend with
tumor immune neoantigens and
microsatellite instability. MSH2's expression in the majority of
tumors is a direct factor to the activation of
tumor-associated pathways as well as immune-associated pathways. MSH2's early screening or even therapeutic target role for
sarcoma (SARC) diagnosis is contributing to the efficiency of early screening and overall survival in SARC patients.